SCHEMBL3564516

SCHEMBL3564516

O=S(=O)(NCc1cccs1)c1ccc(-c2nc3ccccc3[nH]2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK2 O96017 5/20 0.71
SMN1; SMN2 Q16637 3/20 0.58
ALDH1A1 P00352 3/20 0.58
MAPT P10636 2/20 0.58
MEN1 O00255 1/20 0.58
NPC1 O15118 1/20 0.58
RAB9A P51151 1/20 0.58
KMT2A Q03164 1/20 0.58
POLB P06746 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
GAA P10253 1/20 0.51
KDM4E B2RXH2 3/20 0.50
LMNA P02545 2/20 0.48
TSHR P16473 2/20 0.48
PTGS2 P35354 1/20 0.48
SCD O00767 1/20 0.47
MMP2 P08253 1/20 0.47
MMP9 P14780 1/20 0.47
MMP8 P22894 1/20 0.47
MMP13 P45452 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5897709 0.84 CHEK2 (0.73) CHEK2SMN1; SMN2ALDH1A1MAPTMEN1
SCHEMBL1381233 0.83 CHEK2 (0.86) CHEK2POLB
SCHEMBL3571725 0.82 CHEK2 (0.68) CHEK2SMN1; SMN2ALDH1A1RAB9AGAA
SCHEMBL5177233 0.81 CHEK2 (0.68) CHEK2SMN1; SMN2ALDH1A1MAPTMEN1
SCHEMBL1379281 0.80 CHEK2 (0.71) CHEK2SMN1; SMN2ALDH1A1MAPTMEN1
SCHEMBL3562499 0.79 CHEK2 (0.68) CHEK2SMN1; SMN2ALDH1A1MAPTNPC1
SCHEMBL3560900 0.79 CHEK2 (0.68) CHEK2SMN1; SMN2ALDH1A1MAPTMEN1
SCHEMBL14484120 0.78 ALDH1A1 (0.66) CHEK2ALDH1A1MAPTMEN1KMT2A
SCHEMBL3571768 0.76 CHEK2 (0.71) CHEK2SMN1; SMN2ALDH1A1MAPTGAA
SCHEMBL3574951 0.76 CHEK2 (0.73) CHEK2SMN1; SMN2ALDH1A1MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7687639-B2 Substituted benzimidazoles and imidazo-[4,5]-pyridines JANSSEN PHARMACEUTICA N.V. (BE) 2010-03-30 US disclosed
US-20060252793-A1 Substituted benzimidazoles and imidazo-[4,5]-pyridines BW CONVERTING AB (SE) 2006-11-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252793-A1 Substituted benzimidazoles and imidazo-[4,5]-pyridines CDKN1A, DDB1, TMBIM6 CHEK2 14/4885SMN1; SMN2 3372/4885ALDH1A1 1427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.